Ayman Al Jurdi

6PUBLICATIONS
9CO-AUTHORS
NeurogeneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmaceutical delivery technologiesInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 04, 2025
Should Nephrology Clinical Trials Account for Apolipoprotein L1 Gene Risk Status?

Everly Ramos, Andrew L Lundquist, Ayman Al Jurdi

|Jul 29, 2025
How I Treat Challenging Cases of Antibody-Mediated Glomerular Diseases.

Harish Seethapathy, Ayman Al Jurdi, Orhan Efe

|Jun 13, 2024
Delayed-Release Budesonide in a Patient With Progressive IgA Nephropathy and Stage 4 Chronic Kidney Disease: A Case Report.

Zohreh Gholizadeh Ghozloujeh, Vinay Srinivasan, Ayman Al Jurdi

|Apr 12, 2024
Successful Treatment of Posttransplant Monoclonal Gammopathy-associated C3 Glomerulopathy With Plasma Cell Clone-directed Therapy.

Ayman Al Jurdi, Abraham Cohen Bucay, Leonardo V Riella

|Sep 02, 2023
Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.

Ayman Al Jurdi, Christopher El Mouhayyar, Orhan Efe

|Jun 21, 2022
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.

Ayman Al Jurdi, Leela Morena, Mariesa Cote

Pageof 1

Frequent Collaborators

2 joint publications

Harish Seethapathy

2 joint publications

Orhan Efe

2 joint publications

Anushya Jeyabalan

1 joint publications

Jamil Azzi